Dr. Lisa Bailey

About Lisa Bailey

Education:

• Earned a PhD in Epidemiology and an MPH in Health Education from the University of California at Berkeley.
• Received an MD from Northwestern University.
• Holds a degree in Mathematics from Northwestern University, 1971.

Experience:

• Has been practicing in the East Bay since 1982, with a focus on breast cancer and breast health.
• Completed a General Surgery residency at McGaw Medical Center of Northwestern University Medical School.
• Finished a Surgical Oncology Fellowship at Evanston Hospital in 1981.
• Served as past president and board member of the California Division of the American Cancer Society.
• Chairs the Breast Cancer Taskforce of the American Cancer Society.
• Is a member of the Commission on Cancer of the American College of Surgeons.

Area of expertise

Affiliated Hospitals

Contra Costa Regional Medical Center

Epic Care-Dublin

Clinical Trials Lisa Bailey is currently running

Symptom Monitoring

for Young Women on Hormone Therapy

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.

Recruiting1 award N/A13 criteria

Fulvestrant + Binimetinib

for Breast Cancer

This phase II ComboMATCH treatment trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone.

Recruiting1 award Phase 219 criteria

More about Lisa Bailey

Other Doctors you might be interested in

Frequently asked questions